Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fibrocell Science (FCSC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,663
  • Shares Outstanding, K 9,758
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,280 K
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.76 +30.11%
on 04/12/19
3.24 -29.32%
on 04/15/19
-0.21 (-8.40%)
since 03/22/19
3-Month
1.63 +40.49%
on 02/07/19
3.28 -30.18%
on 03/20/19
+0.36 (+18.65%)
since 01/24/19
52-Week
1.45 +57.93%
on 12/31/18
5.17 -55.71%
on 05/25/18
-0.66 (-22.37%)
since 04/24/18

Most Recent Stories

More News
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

Key highlights of the past week are collaborations and pipeline updates.

CELG : 93.10 (-0.61%)
NVO : 48.37 (-0.60%)
VRTX : 172.58 (-1.59%)
GILD : 62.80 (-0.38%)
FCSC : 2.29 (+3.15%)
BMY : 44.62 (-1.54%)
AXSM : 16.04 (+0.63%)
ProQR Initiates Dosing in Phase II/III Eye Disorder Study

ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

PRQR : 11.47 (-1.80%)
EXEL : 20.55 (-3.97%)
CLSN : 2.36 (-0.84%)
FCSC : 2.29 (+3.15%)
Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.

PDLI : 3.37 (-3.16%)
XON : 4.32 (-2.04%)
MRUS : 15.89 (-0.06%)
FCSC : 2.29 (+3.15%)
Thinking about buying stock in Advanced Disposal Services Inc., Bank of America Corp., Canopy Growth Corp., Fibrocell Science, or Johnson & Johnson?

InvestorsObserver issues critical PriceWatch Alerts for ADSW, BAC, CGC, FCSC, and JNJ.

BAC : 30.02 (-0.17%)
JNJ : 139.20 (-0.50%)
ADSW : 32.31 (-0.52%)
FCSC : 2.29 (+3.15%)
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share -

XON : 4.32 (-2.04%)
FCSC : 2.29 (+3.15%)
Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors

- Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Governance Experts -

XON : 4.32 (-2.04%)
FCSC : 2.29 (+3.15%)
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference

Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski,...

XON : 4.32 (-2.04%)
FCSC : 2.29 (+3.15%)
Fibrocell to Present at Phacilitate Leaders World 2019

Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski,...

XON : 4.32 (-2.04%)
FCSC : 2.29 (+3.15%)
Intrexon Announces First Quarter 2018 Financial Results

Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its first quarter financial results...

AQB : 2.30 (-2.54%)
XON : 4.32 (-2.04%)
FCSC : 2.29 (+3.15%)
Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights

Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the...

XON : 4.32 (-2.04%)
FCSC : 2.29 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade FCSC with:

Business Summary

Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous...

See More

Key Turning Points

2nd Resistance Point 2.53
1st Resistance Point 2.41
Last Price 2.29
1st Support Level 2.16
2nd Support Level 2.04

See More

52-Week High 5.17
Fibonacci 61.8% 3.75
Fibonacci 50% 3.31
Fibonacci 38.2% 2.87
Last Price 2.29
52-Week Low 1.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar